Fitness Trends Thyroid Cancer Drugs Market | Page 3

estimated 765,547 people living with thyroid cancer in the U.S. Moreover, according to the
same source, an estimated 53,990 new cases of thyroid cancer are expected to be registered in
2018, representing 3.1% of all new cancer cases, in 2018.
Request For Customization of Research Report @
https://www.coherentmarketinsights.com/insight/request-customization/1710
Thyroid Cancer Drugs Market Competitive Landscape
Some of the key players operating in thyroid cancer drugs market include Biovista, Vascular
Biogenics, Azaya Therapeutics, Bionomics, Bayer, Eisai, Bio-Path Holdings, Takeda
Pharmaceutical Company, GlaxoSmithKline plc, and AstraZeneca plc. Key players in the market
are focusing on organic growth strategies, in order to enhance its market share and retain its
position in the market. For instance, in May 2016, U.S. Food and Drug Administration (FDA)
granted Orphan Drug Designation for AstraZeneca’s investigational MEK 1/2 inhibitor,
selumetinib for adjuvant treatment of patients with stage III or IV differentiated thyroid cancer
(DTC). Moreover, in April 2011, FDA approved AstraZeneca’s kinase inhibitor vandetanib for the
treatment of unresectable or metastatic medullary thyroid cancer.
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-
ready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: [phone]
Email: [e-mail]